MCID: PLM012
MIFTS: 54

Pulmonary Sarcoidosis malady

Categories: Immune diseases, Respiratory diseases

Aliases & Classifications for Pulmonary Sarcoidosis

Aliases & Descriptions for Pulmonary Sarcoidosis:

Name: Pulmonary Sarcoidosis 38 12 14
Sarcoidosis, Pulmonary 42 69
Sarcoidosis Pulmonary 52
Lung Sarcoidosis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:13406
ICD10 33 D86.0 D86.2
MeSH 42 D017565
NCIt 47 C34997
SNOMED-CT 64 187230004 24369008
UMLS 69 C0036205

Summaries for Pulmonary Sarcoidosis

MalaCards based summary : Pulmonary Sarcoidosis, also known as sarcoidosis, pulmonary, is related to tuberculosis and pulmonary tuberculosis. An important gene associated with Pulmonary Sarcoidosis is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Dexmedetomidine and Epinephrine have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and lymph node, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and hematopoietic system

Related Diseases for Pulmonary Sarcoidosis

Diseases related to Pulmonary Sarcoidosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 250)
id Related Disease Score Top Affiliating Genes
1 tuberculosis 29.7 ACE CCL2 IL2 TNF
2 pulmonary tuberculosis 29.6 CCL5 IFNG TNF
3 hepatitis 29.5 IFNG IL2 TNF
4 membranoproliferative glomerulonephritis 29.4 CCR5 CSF2 IL2 TNF
5 sarcoma 29.4 CSF2 IL2
6 rheumatoid arthritis 28.0 CCL2 CCL5 CSF2 CXCL5 ICAM1 IFNG
7 asymptomatic neurosyphilis 10.3 IFNG IL2RA
8 stocco dos santos syndrome 10.3 IFNG TNF
9 cutaneous candidiasis 10.3 CCL2 ICAM1
10 hypotrichosis 4 10.3 ICAM1 IFNG TNF
11 neurotic disorder 10.3 ICAM1 IFNG TNF
12 conduct disorder 10.3 ICAM1 IFNG TNF
13 urethral intrinsic sphincter deficiency 10.3 CCL2 IFNG TNF
14 burns 10.2 CXCR3 IFNG TNF
15 steatitis 10.2 IL2 TNF
16 immune-complex glomerulonephritis 10.2 CCL2 CXCR3 IFNG
17 vps11-related autosomal recessive hypomyelinating leukodystrophy 10.2 CCL5 TNF
18 hallucinogen dependence 10.2 CCR5 IFNG TNF
19 uveitis 10.2 CCL2 ICAM1 TNF
20 aniseikonia 10.2 CSF2 IFNG TNF
21 esophagus lymphoma 10.2 CSF2 IFNG TNF
22 vulvar nodular hidradenoma 10.2 IFNG IL2RA TNF
23 amelogenesis imperfecta 10.2 CCL2 ICAM1 TNF
24 benign secondary hypertension 10.2 CCL2 CCR5 ICAM1
25 choanal atresia, bilateral 10.2 CCL2 IL2RA TNF
26 chromophobe adenoma 10.2 ICAM1 IL2
27 respiratory system disease 10.2 IFNG IL2RA TNF
28 optic nerve hypoplasia 10.2 CCL2 ICAM1 TNF
29 pulmonary eosinophilia 10.2 CCL2 IFNG TNF
30 autosomal dominant deafness-onychodystrophy syndrome 10.2 IFNG IL2 TNF
31 pyoderma gangrenosum 10.2 CSF2 IFNG TNF
32 plantar wart 10.2 IFNG IL2 TNF
33 clostridium difficile colitis 10.2 IFNG IL2 TNF
34 amyotrophic lateral sclerosis type 14 10.2 IFNG IL2 TNF
35 tularemia 10.2 IFNG IL2 TNF
36 pulpitis 10.2 CCL5 IFNG TNF
37 paralytic poliomyelitis 10.2 IFNG IL2
38 oral cavity cancer 10.2 CXCR3 ICAM1 IFNG TNF
39 tau syndrome 10.2 IL18 TNF
40 abnormal retinal correspondence 10.2 IFNG IL2 TNF
41 balkan nephropathy 10.2 CXCR3 ICAM1 IFNG TNF
42 parasitic protozoa infectious disease 10.2 CXCR3 ICAM1 IFNG TNF
43 orbital osteomyelitis 10.2 IFNG IL2 TNF
44 caplan's syndrome 10.2 IFNG IL2
45 nasopharyngitis 10.2 IFNG IL2 TNF
46 dengue hemorrhagic fever 10.1 IFNG IL2 TNF
47 chronic lymphocytic leukemia 10.1 CSF2 IFNG TNF
48 liver inflammatory pseudotumor 10.1 IFNG IL2 TNF
49 latent syphilis 10.1 CCL5 CXCR3 ICAM1
50 blue toe syndrome 10.1 IFNG IL2 TNF

Graphical network of the top 20 diseases related to Pulmonary Sarcoidosis:



Diseases related to Pulmonary Sarcoidosis

Symptoms & Phenotypes for Pulmonary Sarcoidosis

GenomeRNAi Phenotypes related to Pulmonary Sarcoidosis according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.7 TNF ACE ICAM1 IL18 IL2 IL2RA
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.7 ACE ICAM1 IL18 IL2 IL2RA TNF

MGI Mouse Phenotypes related to Pulmonary Sarcoidosis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.18 ACE CCL5 CCR5 CSF2 CXCR3 ICAM1
2 immune system MP:0005387 10.13 SFTPD TNF ACE CCL2 CCL5 CCR5
3 cardiovascular system MP:0005385 10.11 IL2 TNF ACE CCR5 CSF2 CXCR3
4 homeostasis/metabolism MP:0005376 10.11 ACE CCR5 CSF2 CXCR3 ICAM1 IFNG
5 mortality/aging MP:0010768 10 CCR5 CSF2 CXCR3 ICAM1 IFNG IL18
6 digestive/alimentary MP:0005381 9.98 CCR5 ICAM1 IFNG IL18 IL2 IL2RA
7 neoplasm MP:0002006 9.76 ACE CCR5 CSF2 CXCR3 ICAM1 IFNG
8 respiratory system MP:0005388 9.5 CSF2 CXCR3 IFNG IL2 IL2RA SFTPD
9 vision/eye MP:0005391 9.17 CCR5 ICAM1 IFNG IL18 IL2 IL2RA

Drugs & Therapeutics for Pulmonary Sarcoidosis

Drugs for Pulmonary Sarcoidosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 193)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
2
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
3
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
4
Remifentanil Approved Phase 4 132875-61-7 60815
5
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
6
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
7
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
8
Benzocaine Approved Phase 4 1994-09-7, 94-09-7 2337
9
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
10
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
11
Azathioprine Approved Phase 4,Phase 2 446-86-6 2265
12
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
13
Nicotine Approved Phase 4,Phase 1,Phase 2 54-11-5 942 89594
14
Acetylcholine Approved Phase 4 51-84-3 187
15 tannic acid Approved, Nutraceutical Phase 4
16 Adrenergic Agents Phase 4,Phase 2,Phase 3,Phase 1
17 Adrenergic Agonists Phase 4
18 Adrenergic alpha-2 Receptor Agonists Phase 4
19 Adrenergic alpha-Agonists Phase 4
20 Analgesics Phase 4,Phase 2,Phase 3
21 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3
22 Analgesics, Opioid Phase 4
23 Anesthetics Phase 4,Phase 2,Phase 3
24 Anesthetics, General Phase 4
25 Anesthetics, Intravenous Phase 4
26 Central Nervous System Depressants Phase 4,Phase 2,Phase 3
27 Epinephryl borate Phase 4
28 Hypnotics and Sedatives Phase 4
29 Narcotics Phase 4
30 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1
31 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Racepinephrine Phase 4
33 Hormone Antagonists Phase 4,Phase 3,Phase 2
34 Hormones Phase 4,Phase 3,Phase 2
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
36 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Platelet Aggregation Inhibitors Phase 4,Phase 2
38 Vasodilator Agents Phase 4,Phase 2,Phase 3,Phase 1
39 Central Nervous System Stimulants Phase 4,Phase 2,Phase 3,Phase 1
40 Dexmethylphenidate Hydrochloride Phase 4
41 Dopamine Agents Phase 4
42 Dopamine Uptake Inhibitors Phase 4
43 Neurotransmitter Uptake Inhibitors Phase 4
44 Cholinergic Agents Phase 4,Phase 1,Phase 2
45 Adrenocorticotropic Hormone Phase 4
46 beta-endorphin Phase 4
47 Melanocyte-Stimulating Hormones Phase 4
48 Nicotinic Agonists Phase 4,Phase 1,Phase 2
49
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
50
Hydroxychloroquine Approved Phase 3 118-42-3 3652

Interventional clinical trials:

(show top 50) (show all 125)
id Name Status NCT ID Phase
1 Safety Evaluation of Dexmedetomidine for EBUS-TBNA Unknown status NCT01381627 Phase 4
2 Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension Completed NCT00403650 Phase 4
3 Use of Focalin for Fatigue in Sarcoidosis Completed NCT00361387 Phase 4
4 Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration for the Diagnosis of Hilar/Mediastinal Lymphadenopathies Completed NCT01658280 Phase 4
5 Fractionated Versus Target-controlled Propofol Administration in Bronchoscopy Completed NCT02246023 Phase 4
6 Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS) Recruiting NCT02188017 Phase 4
7 Riociguat for Sarcoidosis Associated Pulmonary Hypertension Recruiting NCT02625558 Phase 4
8 Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS) Active, not recruiting NCT01830959 Phase 4
9 Use of CXCL9 as a Biomarker of Acthar Efficacy Not yet recruiting NCT02523092 Phase 4
10 Study of Nicotine Patches in Patients With Sarcoidosis Suspended NCT00701207 Phase 4
11 Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD") Terminated NCT00747461 Phase 4
12 Low-dose Dexamethasone in Newly Diagnosed Pulmonary Sarcoidosis Unknown status NCT01920919 Phase 3
13 Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension Unknown status NCT00851929 Phase 2, Phase 3
14 Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). Completed NCT02200146 Phase 3
15 Antibody Response to Influenza Vaccine in Patients With Sarcoidosis Completed NCT00828828 Phase 3
16 Trial for the Diagnosis of Sarcoidosis Completed NCT00872612 Phase 3
17 Tadalafil for Sarcoidosis Associated Pulmonary Hypertension Completed NCT01324999 Phase 2, Phase 3
18 Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension Completed NCT00581607 Phase 2, Phase 3
19 A Study of Infliximab in Patients With Sarcoidosis Completed NCT00073437 Phase 3
20 Efficacy and Safety of Influenza Vaccine During Sarcoidosis Completed NCT01687517 Phase 3
21 Use of Armodafinil for Fatigue in Sarcoidosis Completed NCT00555347 Phase 2, Phase 3
22 SARCOTHAL. Thalidomide in Skin Sarcoidosis Completed NCT00305552 Phase 3
23 A Trial on Clinical Efficacy of 1% Versus 2% Lignocaine in Cough Suppression and Pain Relief in Patients Undergoing Flexible Bronchoscopy Completed NCT01955824 Phase 2, Phase 3
24 The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis Completed NCT00794274 Phase 2, Phase 3
25 Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease) Completed NCT01052428 Phase 2, Phase 3
26 Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis Recruiting NCT02824419 Phase 2, Phase 3
27 Mycophenolate for Pulmonary Sarcoidosis Terminated NCT00262132 Phase 3
28 Atorvastatin to Treat Pulmonary Sarcoidosis Completed NCT00279708 Phase 2
29 Treatment of Pulmonary Sarcoidosis With Pentoxifylline Completed NCT00001877 Phase 2
30 Rituximab for Pulmonary Sarcoidosis Completed NCT00855205 Phase 2
31 A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis Completed NCT00955279 Phase 2
32 Diffuse Fibrotic Lung Disease Completed NCT00000596 Phase 2
33 A Study of Adalimumab to Treat Sarcoidosis of the Skin Completed NCT00274352 Phase 2
34 Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis Recruiting NCT02024555 Phase 2
35 Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis Recruiting NCT02888080 Phase 2
36 Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study Recruiting NCT02265874 Phase 1, Phase 2
37 SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma Active, not recruiting NCT01362790 Phase 1, Phase 2
38 Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability Suspended NCT01615484 Phase 2
39 A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis Terminated NCT01732211 Phase 2
40 Safety and Efficacy Study of Bosentan in Progressive Pulmonary Sarcoidosis Terminated NCT00926627 Phase 2
41 Safety Study of Abatacept to Treat Refractory Sarcoidosis Terminated NCT00739960 Phase 2
42 Trial of Adalimumab in Progressive Sarcoidosis Terminated NCT00311246 Phase 2
43 Evaluation of the Diagnostic Utility of INS316 in Patients With Interstitial Lung Diseases (01-701) Terminated NCT01381666 Phase 2
44 Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis Terminated NCT00282438 Phase 1, Phase 2
45 Clinical Trial to Assess the Efficacy of Rituximab and Azathioprine in the Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease (GLILD) in Adult Patients With Common Variable Immunodeficiency (CVID) Withdrawn NCT02789397 Phase 2
46 Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis Completed NCT01169038 Phase 1
47 A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma Completed NCT01051934 Phase 1
48 Effects of Propranolol (vs. Placebo) on Information Processing During Presentation of Emotionally Arousing Pictures Completed NCT02509559 Phase 1
49 SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma Completed NCT01445392 Phase 1
50 Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors Completed NCT00066651 Phase 1

Search NIH Clinical Center for Pulmonary Sarcoidosis

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Pulmonary Sarcoidosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Pulmonary Sarcoidosis:
PDA001, Placenta-derived cells for pulmonary sarcoidosis
Embryonic/Adult Cultured Cells Related to Pulmonary Sarcoidosis:
Placenta-derived cells PMIDs: 22469567

Cochrane evidence based reviews: sarcoidosis, pulmonary

Genetic Tests for Pulmonary Sarcoidosis

Anatomical Context for Pulmonary Sarcoidosis

MalaCards organs/tissues related to Pulmonary Sarcoidosis:

39
Lung, T Cells, Lymph Node, Testes, Monocytes, Neutrophil, Breast

Publications for Pulmonary Sarcoidosis

Articles related to Pulmonary Sarcoidosis:

(show top 50) (show all 600)
id Title Authors Year
1
Bioinformatics analysis of gene expression profile data to screen key genes involved in pulmonary sarcoidosis. ( 27682024 )
2017
2
Pulmonary sarcoidosis: an update. ( 27766929 )
2017
3
Osteoprotegerin/sRANKL Signaling System in Pulmonary Sarcoidosis: A Bronchoalveolar Lavage Study. ( 27826889 )
2017
4
Strategies for identifying pulmonary sarcoidosis patients at risk for severe or chronic disease. ( 28076979 )
2017
5
Spontaneous resolution of a tumor like pulmonary sarcoidosis. ( 27758997 )
2016
6
Fungal cell wall agents and bacterial lipopolysaccharide in organic dust as possible risk factors for pulmonary sarcoidosis. ( 27688795 )
2016
7
Pulmonary sarcoidosis induced by the anti-PD-1 monoclonal antibody pembrolizumab or post-immunotherapy granulomatous reaction: which is more appropriate terminology? ( 27143637 )
2016
8
Expression Profile of Six RNA-Binding Proteins in Pulmonary Sarcoidosis. ( 27575817 )
2016
9
Altered miRNA expression in pulmonary sarcoidosis. ( 26768132 )
2016
10
Pulmonary metastases from low grade sarcoma in a patient with pulmonary sarcoidosis. Sarcoidosis or sarcoid-like reaction? ( 27537721 )
2016
11
CTAS: a CT score to quantify disease activity in pulmonary sarcoidosis. ( 27701118 )
2016
12
Effects of radiological extent on neutrophil/lymphocyte ratio in pulmonary sarcoidosis. ( 26957274 )
2016
13
Pulmonary Sarcoidosis is Associated With Exosomal Vitamin D-Binding Protein and Inflammatory Molecules. ( 27566455 )
2016
14
Predictors of objective cough frequency in pulmonary sarcoidosis. ( 26846840 )
2016
15
Fatigue and health-related quality of life in patients with pulmonary sarcoidosis treated by oral Corticosteroids. ( 27537714 )
2016
16
Assessment of right ventricular systolic and diastolic parameters in pulmonary sarcoidosis. ( 26912008 )
2016
17
Clinical management of pulmonary sarcoidosis. ( 26959110 )
2016
18
Clinical Features of Ocular Sarcoidosis in Patients with Biopsy-proven Pulmonary Sarcoidosis in Serbia. ( 27191355 )
2016
19
Altered Cyclooxygenase-2 Expression in Pulmonary Sarcoidosis is not Related to Clinical Classifications. ( 27188849 )
2016
20
Clinical significance of the "galaxy sign" in patients with pulmonary sarcoidosis in a Japanese single-center cohort. ( 27758990 )
2016
21
Exhaled nitric oxide is not increased in pulmonary sarcoidosis. ( 27055834 )
2016
22
Functional TLR9 Expression and CXCR3 Ligand Release in Pulmonary Sarcoidosis. ( 27390897 )
2016
23
Nephrology: Instructive case haemorrhagic cystitis due to BK virus in an adult with cardiac & pulmonary sarcoidosis. ( 27546780 )
2016
24
Pulmonary mucosa-associated lymphoid tissue lymphoma associated with pulmonary sarcoidosis: a case report and literature review. ( 27067783 )
2016
25
Osteoprotegerin/sRANKL Signaling System in Pulmonary Sarcoidosis: A Bronchoalveolar Lavage Study. ( 27645544 )
2016
26
Treatment indications for pulmonary sarcoidosis. ( 27055843 )
2016
27
Pulmonary sarcoidosis: calcification within the galaxy sign. ( 27979849 )
2016
28
The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without LAPfgren's Syndrome. ( 28050119 )
2016
29
Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab. ( 27091806 )
2016
30
The effect of an oral anti-oxidant, N-Acetyl-cysteine, on inflammatory and oxidative markers in pulmonary sarcoidosis. ( 26831541 )
2016
31
Osteoprotegerin/sRANKL Signaling System in Pulmonary Sarcoidosis: A Bronchoalveolar Lavage Study. ( 27401080 )
2016
32
Pulmonary sarcoidosis presenting with acute respiratory distress syndrome. ( 26933462 )
2016
33
Pulmonary Sarcoidosis: Diagnosis and Treatment. ( 27378039 )
2016
34
Pulmonary sarcoidosis or post-immunotherapy granulomatous reaction induced by the anti-PD-1 monoclonal antibody pembrolizumab: the terminology is not the key point. ( 27551050 )
2016
35
T-cell receptor-HLA-DRB1 associations suggest specific antigens in pulmonary sarcoidosis. ( 26585430 )
2016
36
Clinical and radiological features of extra-pulmonary sarcoidosis: a pictorial essay. ( 27222055 )
2016
37
Pulmonary hypertension complicating pulmonary sarcoidosis. ( 27194118 )
2016
38
99mTc-anti-TNF-I+ antibody for the imaging of disease activity in pulmonary sarcoidosis. ( 26797030 )
2016
39
Lung transplantation for pulmonary sarcoidosis. Twenty-five years of experience in the USA. ( 26781176 )
2016
40
Refractory pulmonary sarcoidosis - proposal of a definition and recommendations for the diagnostic and therapeutic approach. ( 26973429 )
2016
41
The Circulating Treg/Th17 Cell Ratio Is Correlated with Relapse and Treatment Response in Pulmonary Sarcoidosis Patients after Corticosteroid Withdrawal. ( 26845566 )
2016
42
Plasma metabolomic profile in fibrosing pulmonary sarcoidosis. ( 27055833 )
2016
43
Adalimumab for refractory pulmonary sarcoidosis. ( 26428728 )
2015
44
TL1A/DR3 axis involvement in the inflammatory cytokine network during pulmonary sarcoidosis. ( 26240517 )
2015
45
Pulmonary sarcoidosis is associated with high-level ICOS expression on lung regulatory T cells - possible implications for the ICOS/ICOS-L axis in disease course and resolution. ( 26415669 )
2015
46
Association of serum TNF-I+, IL-8 and free light chain with HLA-DR B alleles expression in pulmonary and extra-pulmonary sarcoidosis. ( 25866481 )
2015
47
Atypical forms of pulmonary sarcoidosis: A diagnostic not to ignore. ( 26375750 )
2015
48
A comparison of conventional transbronchial vs endobronchial, endoscopic ultrasound-guided needle aspiration in the diagnosis of pulmonary sarcoidosis: a randomized trial. ( 25792254 )
2015
49
CD34+ progenitor cells in pulmonary sarcoidosis. ( 26039017 )
2015
50
Use of Lenalidomide in 5q-Myelodysplastic Syndrome Provides Novel Treatment Prospects in Management of Pulmonary Sarcoidosis. ( 26238834 )
2015

Variations for Pulmonary Sarcoidosis

Expression for Pulmonary Sarcoidosis

Search GEO for disease gene expression data for Pulmonary Sarcoidosis.

Pathways for Pulmonary Sarcoidosis

Pathways related to Pulmonary Sarcoidosis according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 CCL2 CCL5 CCR5 CSF2 ICAM1 IFNG
2
Show member pathways
13.84 CCL2 CCL5 CCR5 CSF2 CXCL5 CXCR3
3
Show member pathways
13.6 CCL2 CCL5 CCR5 CSF2 CXCL5 CXCR3
4
Show member pathways
13.53 CCL2 CCL5 ICAM1 IFNG IL18 IL2
5
Show member pathways
13.36 CCL2 CCL5 CCR5 CSF2 CXCL5 CXCR3
6
Show member pathways
13.29 CCL2 CCL5 CCR5 CSF2 ICAM1 IFNG
7
Show member pathways
13.17 CCL2 CCL5 CCR5 CSF2 CXCL5 CXCR3
8
Show member pathways
12.95 ACE CCL2 CCL5 IFNG IL2 SFTPD
9
Show member pathways
12.87 CCL2 CCL5 CCR5 CXCL5 CXCR3
10
Show member pathways
12.85 ICAM1 IFNG IL2 IL2RA TNF
11
Show member pathways
12.75 CCL2 CCL5 ICAM1 IFNG IL18 IL2
12
Show member pathways
12.65 IFNG IL18 IL2 IL2RA TNF
13
Show member pathways
12.63 IFNG IL18 IL2 IL2RA TNF
14
Show member pathways
12.62 CCL2 IFNG IL18 IL2 TNF
15 12.59 CCL2 CCL5 IFNG IL2 IL2RA TNF
16
Show member pathways
12.55 CSF2 ICAM1 IFNG IL2 TNF
17
Show member pathways
12.47 CCR5 CSF2 IFNG IL2 TNF
18 12.46 CSF2 ICAM1 IL2 IL2RA TNF
19
Show member pathways
12.38 CCL2 CSF2 CXCL5 IFNG TNF
20
Show member pathways
12.37 CCL2 CCL5 ICAM1 IFNG IL2 TNF
21
Show member pathways
12.24 CSF2 IFNG IL2 IL2RA
22
Show member pathways
12.19 IFNG IL18 IL2 TNF
23 12.13 CCL2 ICAM1 IFNG TNF
24
Show member pathways
12.1 CCL2 CCL5 CCR5 CXCL5 CXCR3
25 12.08 CCL2 ICAM1 IFNG IL2 TNF
26 12.06 CSF2 IFNG IL2 IL2RA TNF
27
Show member pathways
12.04 CCR5 IFNG IL18 IL2 IL2RA
28
Show member pathways
12.03 IFNG IL2 IL2RA
29 12.03 CCL2 ICAM1 IL18 TNF
30
Show member pathways
12 IFNG IL18 IL2 TNF
31 11.9 CCL2 ICAM1 TNF
32 11.89 CSF2 IL2RA TNF
33 11.88 CSF2 IFNG TNF
34 11.87 CSF2 ICAM1 IFNG IL2
35 11.83 CSF2 IFNG IL18
36 11.83 CCL2 CCL5 CSF2 CXCL5 ICAM1 TNF
37 11.82 CSF2 IFNG IL2 TNF
38
Show member pathways
11.82 CSF2 IFNG IL2 IL2RA TNF
39 11.74 CCL2 CCL5 CSF2 TNF
40 11.73 ICAM1 IL2RA TNF
41
Show member pathways
11.72 IFNG IL2 IL2RA TNF
42 11.71 IFNG IL2 IL2RA
43
Show member pathways
11.69 CSF2 ICAM1 IFNG IL2 TNF
44 11.6 CCL2 IFNG IL18 TNF
45 11.59 IFNG IL2 TNF
46 11.56 IFNG IL2 TNF
47 11.55 IFNG IL2 IL2RA
48 11.54 CXCR3 IFNG IL18 IL2 IL2RA TNF
49 11.52 CCL2 ICAM1 IFNG IL18 TNF
50 11.43 ICAM1 IFNG IL18 TNF

GO Terms for Pulmonary Sarcoidosis

Cellular components related to Pulmonary Sarcoidosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 ACE CCL2 CCL5 CSF2 CXCL5 IFNG
2 cell surface GO:0009986 9.65 CCR5 CXCR3 ICAM1 IL2RA TNF
3 external side of plasma membrane GO:0009897 9.5 ACE CCR5 CXCR3 ICAM1 IFNG IL2RA
4 extracellular space GO:0005615 9.36 ACE CCL2 CCL5 CSF2 CXCL5 ICAM1

Biological processes related to Pulmonary Sarcoidosis according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
id Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.96 CCL5 CCR5 CXCL5 IL18 IL2
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.92 CCL2 CCL5 ICAM1 TNF
3 cell surface receptor signaling pathway GO:0007166 9.92 CCL2 CCR5 CXCR3 IFNG IL2RA
4 response to ethanol GO:0045471 9.88 CCL2 ICAM1 IL2
5 cellular response to tumor necrosis factor GO:0071356 9.88 CCL2 CCL5 ICAM1
6 response to virus GO:0009615 9.87 CCL5 IFNG TNF
7 cellular response to interleukin-1 GO:0071347 9.85 CCL2 CCL5 ICAM1
8 chemotaxis GO:0006935 9.85 CCL2 CCL5 CCR5 CXCL5 CXCR3
9 regulation of insulin secretion GO:0050796 9.84 CCL5 IFNG TNF
10 cell chemotaxis GO:0060326 9.83 CCL2 CCL5 CXCL5
11 neutrophil chemotaxis GO:0030593 9.83 CCL2 CCL5 IFNG
12 cellular response to interferon-gamma GO:0071346 9.83 CCL2 CCL5 ICAM1
13 positive regulation of smooth muscle cell proliferation GO:0048661 9.82 CCL5 IL18 TNF
14 cellular response to organic cyclic compound GO:0071407 9.81 CCL2 CCL5 IL18 TNF
15 humoral immune response GO:0006959 9.8 CCL2 IFNG TNF
16 positive regulation of interferon-gamma production GO:0032729 9.79 IL18 IL2 TNF
17 positive regulation of nitric oxide biosynthetic process GO:0045429 9.78 ICAM1 IFNG TNF
18 positive regulation of T cell proliferation GO:0042102 9.78 CCL5 IFNG IL2 IL2RA
19 chemokine-mediated signaling pathway GO:0070098 9.77 CCL2 CCL5 CCR5 CXCL5 CXCR3
20 inflammatory response GO:0006954 9.76 CCL2 CCL5 CCR5 CXCL5 CXCR3 IL18
21 protein kinase B signaling GO:0043491 9.75 CCL2 CCL5 TNF
22 positive regulation of cell adhesion GO:0045785 9.73 CCL2 CCL5 IFNG TNF
23 cellular response to lipopolysaccharide GO:0071222 9.73 CCL2 CCR5 CSF2 ICAM1 IFNG TNF
24 cellular response to interleukin-6 GO:0071354 9.72 CCL2 ICAM1
25 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.72 CCL5 CSF2 IFNG IL18 IL2
26 positive regulation of T cell differentiation GO:0045582 9.71 IL2 IL2RA
27 positive regulation of monocyte chemotaxis GO:0090026 9.71 CCL2 CCL5
28 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.71 CSF2 IL2
29 dendritic cell chemotaxis GO:0002407 9.71 CCL5 CCR5
30 positive regulation of activated T cell proliferation GO:0042104 9.71 IL18 IL2 IL2RA
31 lipopolysaccharide-mediated signaling pathway GO:0031663 9.71 CCL2 CCL5 IL18 TNF
32 negative regulation of growth of symbiont in host GO:0044130 9.7 IFNG TNF
33 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.7 IFNG TNF
34 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.7 CSF2 IL18
35 positive regulation of macrophage chemotaxis GO:0010759 9.69 CCL2 CCL5
36 positive regulation of interleukin-17 production GO:0032740 9.69 IL18 IL2
37 positive regulation of podosome assembly GO:0071803 9.68 CSF2 TNF
38 neutrophil mediated immunity GO:0002446 9.68 ACE CXCL5
39 positive regulation of chemokine biosynthetic process GO:0045080 9.68 IFNG TNF
40 positive regulation of isotype switching to IgG isotypes GO:0048304 9.68 IFNG IL2
41 macrophage chemotaxis GO:0048246 9.67 CCL2 CCL5 SFTPD
42 positive regulation of cellular extravasation GO:0002693 9.66 CCL2 ICAM1
43 receptor-mediated virion attachment to host cell GO:0046813 9.64 ACE ICAM1
44 negative regulation of lymphocyte proliferation GO:0050672 9.64 IL2 IL2RA
45 positive regulation of tissue remodeling GO:0034105 9.63 IL18 IL2
46 positive regulation of interleukin-23 production GO:0032747 9.62 CSF2 IFNG
47 regulation of T cell homeostatic proliferation GO:0046013 9.6 IL2 IL2RA
48 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.59 ICAM1 TNF
49 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.58 IFNG TNF
50 MAPK cascade GO:0000165 9.56 CCL2 CCL5 CCR5 CSF2 IL18 IL2

Molecular functions related to Pulmonary Sarcoidosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.33 CSF2 IL2 IL2RA
2 cytokine activity GO:0005125 9.23 CCL2 CCL5 CSF2 CXCL5 IFNG IL18
3 chemokine activity GO:0008009 9.13 CCL2 CCL5 CXCL5

Sources for Pulmonary Sarcoidosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....